Nizatidine

Evidence Level: L1

Predicted Indications: 7

Nizatidine
Nizatidine: From Established H2-Antagonist Therapy to Active Peptic Ulcer Disease

## Pharmacist Assessment Report

Nizatidine: From Established H2-Antagonist Therapy to Active Peptic Ulcer Disease

One-Sentence Summary

Nizatidine is a histamine H2-receptor antagonist; detailed original-indication and regulatory data are not available in this evidence pack, and the drug is currently not marketed in Taiwan. The TxGNN model’s top prediction is Active Peptic Ulcer Disease, which — importantly — appears to be the drug’s own well-established core indication for this class rather than a genuinely novel target, supported by 0 clinical trials and 19 publications (including 4 completed RCTs).

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (no Taiwan license record; DrugBank indication text not retrieved)
Predicted New Indication	Active Peptic Ulcer Disease
TxGNN Prediction Score	99.96%
Evidence Level	L1
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a data gap in this pack). Based on the information that is available, Nizatidine is a histamine H2-receptor antagonist that inhibits basal, nocturnal, and stimulated gastric acid secretion by blocking histamine’s action on parietal cells — the standard pharmacological mechanism underlying acid-suppressive therapy for peptic ulcer disease.

The evidence pack’s own rationale for this prediction is explicit and important: it states that acid suppression via H2-antagonism is the “core, already-established indication” for this drug class, and that this candidate is “not a repurposing signal in the typical sense.” In other words, the model has correctly re-identified the drug’s known pharmacology rather than surfaced a genuinely new therapeutic use. This is a useful validation signal for the TxGNN model’s accuracy, but it should not be read as a novel repurposing opportunity.

For context, several other lower-ranked candidates in this pack (e.g., gastroduodenitis, L2 evidence; gastrojejunal ulcer, L3 evidence) sit closer to genuine extrapolation — acid-related mucosal injury outside the classic duodenal/gastric ulcer population — and may be more informative if the goal is to find an actual new indication rather than confirm the existing one.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2570656	1989	RCT	Clin Pharmacol Ther	Two-phase, placebo-controlled RCT: nizatidine 150mg BID healed active duodenal ulcers over 4–8 weeks
1526089	1992	RCT	Clin Pharmacol Ther	8-week multicenter RCT: nizatidine 150mg BID or 300mg qHS vs placebo healed active benign gastric ulcer
2892259	1987	RCT	Scand J Gastroenterol Suppl	1-year maintenance RCT (n=513): nizatidine 150mg qHS cut duodenal ulcer recurrence to 34% vs 64% with placebo at 12 months
1982108	1990	RCT	Hepato-gastroenterology	8-week RCT: nizatidine (150mg BID or 300mg qHS) comparable to ranitidine 150mg BID for gastric ulcer healing
9198292	1997	RCT (combination therapy)	Chinese Medical Journal	Clarithromycin-based combination regimen for H. pylori eradication in peptic ulcer disease
7960687	1994	RCT / Mechanistic	Isr J Med Sci	Placebo-controlled RCT: nizatidine 300mg qHS promoted duodenal ulcer healing and altered mucosal inflammatory mediators
15683433	2005	RCT	J Gastroenterol Hepatol	Multicenter RCT: nizatidine vs famotidine for maintenance therapy of erosive esophagitis
2905640	1988	Review	Drugs	Pharmacodynamic/pharmacokinetic review establishing nizatidine’s role in peptic ulcer disease
2184124	1990	Review	Gastroenterol Clin North Am	Overview of medical therapy for peptic ulcer disease, situating nizatidine among H2-antagonists
8097411	1993	Review	Bailliere’s Clin Gastroenterol	Review of gastric acid secretion pharmacology (histamine/gastrin/acetylcholine pathways)

India Market Information

Currently no registrations recorded (market status: Not Marketed; total registrations: 0)

Safety Considerations

Drug Interactions: 263 documented interactions on record. Two are rated Major: Atazanavir and Dasatinib. Several are rated Moderate, including a cluster of oral cephalosporins that may be affected by acid suppression (Cefditoren, Cefpodoxime, Cefuroxime), plus Acalabrutinib, Bosutinib, Brigatinib, Ceritinib, Chlorpropamide, and Dabrafenib/Dacomitinib. The remainder are rated Minor (e.g., Ketorolac, Ibuprofen, Diclofenac, Alendronic acid, Axitinib, Cyanocobalamin, Magnesium oxide, Oxaprozin).

No TFDA-sourced warnings or contraindications are available in this evidence pack (flagged as a Blocking data gap — DG001).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top-ranked prediction is backed by strong historical clinical evidence (4 completed RCTs, L1), but it represents the drug’s already-established core H2-antagonist indication rather than a novel repurposing candidate — so the “new indication” framing needs to be qualified before any downstream use. Separately, a Blocking data gap (missing TFDA label warnings/contraindications) prevents a full safety assessment, and the drug is not currently marketed in Taiwan.

To proceed, the following is needed:

TFDA-equivalent label data (warnings, contraindications) to clear the Blocking gap (DG001)
Confirmed mechanism-of-action documentation from DrugBank (DG002)
A decision on whether this candidate is being pursued as a genuine repurposing opportunity or a market-entry case (since the predicted indication overlaps with known drug-class use)
If genuine repurposing is the goal, prioritize review of the lower-confidence but more novel candidates in this pack (e.g., gastroduodenitis, L2; gastrojejunal ulcer, L3) instead of this top-ranked, non-novel result
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.